291 related articles for article (PubMed ID: 35575047)
1. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil.
Sato K; Inoue J; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Ouchi K; Masamune A
Clin J Gastroenterol; 2023 Oct; 16(5):720-725. PubMed ID: 37480423
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report.
Suzuki Y; Ishiguro S; Shimada H; Ohgami M; Suzuki M
Cancer Chemother Pharmacol; 2024 Jun; 93(6):633-638. PubMed ID: 38148336
[TBL] [Abstract][Full Text] [Related]
4. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
Li M; Wong D; Vogel AS; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Hepatology; 2022 Mar; 75(3):531-540. PubMed ID: 34709662
[TBL] [Abstract][Full Text] [Related]
5. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
[TBL] [Abstract][Full Text] [Related]
6. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
7. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T
Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983
[TBL] [Abstract][Full Text] [Related]
8. Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab.
Nakashima K; Demura Y; Oi M; Tabata M; Tada T; Shiozaki K; Akai M; Ishizuka T
Intern Med; 2020 Dec; 59(23):3055-3059. PubMed ID: 32727989
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroid-resistant immune-related adverse events: a systematic review.
Daetwyler E; Wallrabenstein T; König D; Cappelli LC; Naidoo J; Zippelius A; Läubli H
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233099
[TBL] [Abstract][Full Text] [Related]
10. Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab.
Tanaka R; Fujisawa Y; Sae I; Maruyama H; Ito S; Hasegawa N; Sekine I; Fujimoto M
Jpn J Clin Oncol; 2017 Feb; 47(2):175-178. PubMed ID: 28173241
[TBL] [Abstract][Full Text] [Related]
11. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
Bagga A; Hari P; Moudgil A; Jordan SC
Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
[TBL] [Abstract][Full Text] [Related]
13. Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: A case report.
Eleftheriotis G; Skopelitis E
Medicine (Baltimore); 2022 Aug; 101(31):e29473. PubMed ID: 35945730
[TBL] [Abstract][Full Text] [Related]
14. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
[TBL] [Abstract][Full Text] [Related]
15. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis.
Mir R; Shaw HM; Nathan PD
Melanoma Res; 2019 Feb; 29(1):102-106. PubMed ID: 30395075
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
Respir Med Case Rep; 2022; 40():101753. PubMed ID: 36217354
[TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]